Plain-English translation of NCT07026240 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is developing and testing a new way to monitor gastric cancer patients after surgery using a simple blood test that looks for cancer DNA in your bloodstream. Researchers want to see if this blood test can catch cancer recurrence or spread earlier than current methods like imaging scans and standard tumor blood markers (CA19-9, CEA, and CA72-4).
Currently, doctors use imaging and certain blood tests to watch for cancer coming back after surgery, but these methods may not catch recurrence early enough. This study aims to find out whether detecting cancer DNA in blood could give patients a head start in treatment by finding problems sooner.
You likely qualify if…
You likely don't qualify if…
You will have blood samples taken at several time points after your gastric cancer surgery. The study will follow you over time to see whether the new blood test detects cancer recurrence or spread, and compare those results to what standard imaging and blood tests show. Your participation involves regular blood draws but no medications or invasive procedures.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Collaborators
Fudan University
Enrollment target
~258 participants
Started
February 2024
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dazhi Xu, MD., PhD,
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.